(NASDAQ: EYPT) Eyepoint's forecast annual revenue growth rate of 213.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Eyepoint's revenue in 2026 is $7,615,000.On average, 14 Wall Street analysts forecast EYPT's revenue for 2026 to be $164,999,674, with the lowest EYPT revenue forecast at $98,597,366, and the highest EYPT revenue forecast at $211,280,071. On average, 13 Wall Street analysts forecast EYPT's revenue for 2027 to be $2,996,571,832, with the lowest EYPT revenue forecast at $164,328,944, and the highest EYPT revenue forecast at $7,526,852,528.
In 2028, EYPT is forecast to generate $22,902,088,962 in revenue, with the lowest revenue forecast at $5,751,513,043 and the highest revenue forecast at $86,188,854,344.